For the millions of older adults who take statins not because they've had a heart attack but simply as a preventive measure, a foundational question has gone unanswered for decades: does continuing this medication past age 75 actually extend life? A rigorous new phase 3 trial published in The Lancet Healthy Longevity now offers the most direct evidence yet — and the answer challenges the default clinical assumption that statin therapy should continue indefinitely.
The SAGA/SITE trial enrolled adults aged 75 and older who had been on statins for primary prevention of atherosclerotic cardiovascular disease (ASCVD) for at least one year, with no prior history of the disease. Conducted across 297 primary care offices in a pragmatic, real-world design, participants were randomized in a 5:4 ratio to either continue or discontinue their statin. The three-year follow-up tracked all-cause mortality as the primary endpoint in a non-inferiority framework — meaning the trial was designed to determine whether stopping statins was no worse than continuing them for overall survival. Individuals with dementia, a life expectancy under three months, or familial hypercholesterolaemia were excluded, meaningfully sharpening the population's relevance.
This trial arrives at a moment when polypharmacy in older adults is under intense scrutiny. Most landmark statin trials enrolled predominantly middle-aged populations, and extrapolating those benefits to septuagenarians and beyond involves substantial biological and clinical assumptions. Statins carry real side-effect burdens in this cohort — muscle pain, drug interactions, and cognitive complaints — that can meaningfully erode quality of life. Non-inferiority designs are appropriately cautious tools here: they don't claim benefit from stopping, only that the harm of stopping may be negligible. Key limitations include the open-label design, potential for healthy-user bias given the eligibility criteria, and whether three years is sufficient to detect diverging cardiovascular event rates. Still, for primary prevention specifically — distinct from secondary prevention where statin benefits remain robust — this trial may shift how clinicians and patients approach deprescribing conversations in later life.
